CARTITUDE-4
-
Early CARVYKTI® Use Leads to Durable 2.5‑Year Treatment‑Free Remission in Relapsed/Refractory Multiple Myeloma
Phase 3 CARTITUDE‑4 data show that a single infusion of CARVYKTI (ciltacabtagene autoleucel) given as second‑line therapy to standard‑risk multiple myeloma patients yields 80.5 % progression‑free survival at 30 months, with all MRD‑negative responders remaining disease‑free. Translational analyses link higher baseline CD4⁺ naïve T‑cells and an activated bone‑marrow microenvironment to improved outcomes. Safety remains consistent (84 % CRS, 13 % ICANS, low grade ≥3 rates). FDA approval now includes earlier‑line use, positioning CARVYKTI for broader market share and supporting future combination and allogeneic trials.
